注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Recursion Pharmaceuticals Inc是一家临床阶段的生物技术公司,通过整合生物学、化学、自动化、机器学习和工程技术来解码生物学,以实现药物发现的工业化。该公司的平台包括Recursion操作系统,其结合先进的基础设施层来生成专有的生物和化学数据集,以及Recursion地图,一套定制软件、算法和机器学习工具。该公司的项目包括REC-994、REC-2282、REC-4881和REC-3599。REC-994是一种口服生物可利用的超氧化物清除剂小分子,正在开发用于治疗肝硬化心肌病(CCM)。REC-2282用于治疗二型神经纤维瘤病。REC-4881用于治疗家族性腺瘤性息肉病。REC-3599用于治疗GM2神经节苷脂沉积症。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Ramon Martin Chavez Marquez | 57 | 2020 | Independent Chair of the Board |
Robert J. Lollini | 70 | 2014 | Member of Business Advisory Panel |
Terry-Ann Burrell | 47 | 2020 | Independent Director |
Joseph P. Miletich | 72 | 2021 | Chairman of Therapeutics Advisory Board |
Anne Carpenter | - | 2014 | Member of Scientific and Technical Advisory Board |
Kirk R. Thomas | - | 2014 | Member of Scientific & Technical Advisory Board |
H. Perry Fell | 67 | 2014 | Member of Business Advisory Panel |
Zavain Dar | 35 | 2016 | Independent Director |
Dean Y. Li | 61 | 2013 | Co-Founder & Independent Director |
Zachary S. Bogue | 49 | 2018 | Independent Director |
Robert M. Hershberg | 62 | 2020 | Independent Director |
Blake C. Borgeson | 42 | 2013 | Co-Founder & Director |
Christopher C. Gibson | 41 | 2013 | Co-Founder, CEO & Director |
Najat Khan | - | 2024 | Chief R&D Officer, Chief Commercial Officer and Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核